{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T22:15:24Z","timestamp":1794694524746,"version":"4.9.1"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.addr.2026.115925","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:32:17Z","timestamp":1782491537000},"page":"115925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities"],"prefix":"10.1016","volume":"236","author":[{"given":"Suyama Prasansali","family":"Mihindukulasooriya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamika","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Plebanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2026.115925_bb0005","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10600","article-title":"PEGylated therapeutics in the clinic","volume":"9","author":"Gao","year":"2024","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.addr.2026.115925_bb0010","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.addr.2026.115925_bb0015","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1007\/s13346-024-01608-8","article-title":"A journey through the history of PEGylated drug delivery nanocarriers","volume":"14","author":"Lopez-Estevez","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.addr.2026.115925_bb0020","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.bioconjchem.3c00174","article-title":"PEGylated lipid nanoparticle formulations: immunological safety and efficiency perspective","volume":"34","author":"Tenchov","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2026.115925_bb0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\u2014the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115925_bb0030","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2026.115925_bb0035","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","article-title":"mRNA vaccines for infectious diseases - advances, challenges and opportunities","volume":"23","author":"Pardi","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2026.115925_bb0040","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115925_bb0045","series-title":"Immunogenicity Assessment for Therapeutic Protein Products: Guidance for Industry","author":"U.S. Food and Drug Administration","year":"2014"},{"key":"10.1016\/j.addr.2026.115925_bb0050","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/s44222-025-00321-6","article-title":"Polyethylene glycol immunogenicity in nanomedicine","volume":"3","author":"Chen","year":"2025","journal-title":"Nat. Rev. Bioeng."},{"key":"10.1016\/j.addr.2026.115925_bb0055","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/wnan.1339","article-title":"Anti-PEG immunity: emergence, characteristics, and unaddressed questions","volume":"7","author":"Yang","year":"2015","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.addr.2026.115925_bb0060","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jconrel.2023.01.012","article-title":"Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice","volume":"354","author":"Ibrahim","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115925_bb0065","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41467-017-00622-4","article-title":"A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol","volume":"8","author":"Chang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115925_bb0070","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.drudis.2014.08.015","article-title":"Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics","volume":"19","author":"Verhoef","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2026.115925_bb0075","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2007.05.015","article-title":"PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner","volume":"122","author":"Ishida","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115925_bb0080","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.imbio.2012.08.274","article-title":"Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon","volume":"218","author":"Shimizu","year":"2013","journal-title":"Immunobiology"},{"key":"10.1016\/j.addr.2026.115925_bb0085","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.imbio.2015.06.005","article-title":"Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells","volume":"220","author":"Shimizu","year":"2015","journal-title":"Immunobiology"},{"key":"10.1016\/j.addr.2026.115925_bb0090","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jconrel.2025.02.001","article-title":"The strategy used by naive anti-PEG antibodies to capture flexible and featureless PEG chains","volume":"380","author":"Liu","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115925_bb0095","doi-asserted-by":"crossref","first-page":"8733","DOI":"10.1021\/acsnano.3c11165","article-title":"Free PEG suppresses anaphylaxis to PEGylated nanomedicine in swine","volume":"18","author":"Shen","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115925_bb0100","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41565-025-01926-z","article-title":"Balancing stealth and targeting to improve nanomedicine efficacy","volume":"20","author":"Ju","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2026.115925_bb0105","first-page":"36","article-title":"Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors","volume":"74","author":"Richter","year":"1984","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.addr.2026.115925_bb0110","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","article-title":"Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents","volume":"9","author":"Garay","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2026.115925_bb0115","doi-asserted-by":"crossref","first-page":"10661","DOI":"10.1021\/acs.analchem.6b03109","article-title":"Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals","volume":"88","author":"Chen","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.addr.2026.115925_bb0120","doi-asserted-by":"crossref","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine","volume":"16","author":"Ju","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115925_bb0125","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.addr.2026.115925_bb0130","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.toxrep.2020.12.022","article-title":"Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma","volume":"8","author":"Fang","year":"2021","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.addr.2026.115925_bb0135","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jconrel.2022.12.039","article-title":"Anti-PEG antibodies before and after a first dose of Comirnaty\u00ae (mRNA-LNP-based SARS-CoV-2 vaccine)","volume":"354","author":"Bavli","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115925_bb0140","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1016\/j.vaccine.2022.08.024","article-title":"mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations","volume":"40","author":"Carre\u00f1o","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2026.115925_bb0145","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41577-022-00825-x","article-title":"Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines","volume":"23","author":"Ju","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2026.115925_bb0150","doi-asserted-by":"crossref","first-page":"27077","DOI":"10.1021\/acsnano.4c11652","article-title":"Blood distribution of SARS-CoV-2 lipid nanoparticle mRNA vaccine in humans","volume":"18","author":"Kent","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115925_bb0155","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1016\/j.vaccine.2023.06.009","article-title":"Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: evidence for immunogenicity of PEG","volume":"41","author":"Kozma","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2026.115925_bb0160","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1021\/acs.molpharmaceut.2c01036","article-title":"Investigating generation of antibodies against the lipid nanoparticle vector following COVID-19 vaccination with an mRNA vaccine","volume":"20","author":"M\u00fcnter","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115925_bb0165","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/10915818251371966","article-title":"Evaluation of plasma polyethylene glycol (PEG) levels in a healthy adult population","volume":"44","author":"Kubesch","year":"2025","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.addr.2026.115925_bb0170","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1021\/acs.molpharmaceut.3c00774","article-title":"Impact of anti-PEG IgM induced via the topical application of a cosmetic product containing PEG derivatives on the antitumor effects of PEGylated liposomal antitumor drug formulations in mice","volume":"21","author":"Gaballa","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115925_bb0175","doi-asserted-by":"crossref","first-page":"0112","DOI":"10.34133\/bmr.0112","article-title":"Impact of pre-existing anti-polyethylene glycol antibodies on the pharmacokinetics and efficacy of a COVID-19 mRNA vaccine (Comirnaty) in vivo","volume":"28","author":"Liu","year":"2024","journal-title":"Biomater. Res."},{"key":"10.1016\/j.addr.2026.115925_bb0180","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00766-z","article-title":"Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats","volume":"8","author":"Wang","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.addr.2026.115925_bb0185","doi-asserted-by":"crossref","first-page":"9315","DOI":"10.1021\/acsnano.9b03942","article-title":"Pseudo-anaphylaxis to polyethylene glycol (PEG)-coated liposomes: roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions","volume":"13","author":"Kozma","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115925_bb0190","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ijpharm.2012.07.049","article-title":"Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs","volume":"436","author":"Suzuki","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115925_bb0195","first-page":"2891","article-title":"Repeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beagles","volume":"7","author":"Zhao","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2026.115925_bb0200","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ijpharm.2014.09.047","article-title":"Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin","volume":"476","author":"Suzuki","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115925_bb0205","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jconrel.2022.12.005","article-title":"The mechanisms of anti-PEG immune response are different in the spleen and the lymph nodes","volume":"353","author":"Grenier","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115925_bb0210","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jconrel.2023.06.027","article-title":"Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route","volume":"360","author":"Takata","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115925_bb0215","first-page":"3533","article-title":"Accelerated blood clearance phenomenon upon cross-administration of PEGylated nanocarriers in beagle dogs","volume":"10","author":"Wang","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2026.115925_bb0220","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jconrel.2012.11.016","article-title":"Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon","volume":"165","author":"Shiraishi","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115925_bb0225","doi-asserted-by":"crossref","first-page":"18419","DOI":"10.1021\/jacs.2c06877","article-title":"Engineering poly(ethylene glycol) nanoparticles for accelerated blood clearance inhibition and targeted drug delivery","volume":"144","author":"Tian","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115925_bb0230","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijpharm.2012.04.049","article-title":"Size-dependent induction of accelerated blood clearance phenomenon by repeated injections of polymeric micelles","volume":"432","author":"Koide","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115925_bb0235","doi-asserted-by":"crossref","first-page":"33257","DOI":"10.1021\/acsnano.4c13214","article-title":"Approaching two decades: biomolecular coronas and bio-Nano interactions","volume":"18","author":"Li","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115925_bb0240","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1039\/D3NH00198A","article-title":"Anti-PEG antibodies enriched in the protein corona of PEGylated nanocarriers impact the cell uptake","volume":"8","author":"Deuker","year":"2023","journal-title":"Nanoscale Horiz."},{"key":"10.1016\/j.addr.2026.115925_bb0245","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jconrel.2018.08.022","article-title":"Anti-polyethylene glycol antibodies alter the protein corona deposited on nanoparticles and the physiological pathways regulating their fate in vivo","volume":"287","author":"Grenier","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115925_bb0250","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1021\/jacs.4c16987","article-title":"Identification of cell receptors responsible for recognition and binding of lipid nanoparticles","volume":"147","author":"Baimanov","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115925_bb0255","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.7150\/thno.22164","article-title":"Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes","volume":"8","author":"Hsieh","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2026.115925_bb0260","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1248\/bpb.b14-00653","article-title":"Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice","volume":"38","author":"Hashimoto","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.addr.2026.115925_bb0265","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12951-025-03209-0","article-title":"Emerging strategies against accelerated blood clearance phenomenon of nanocarrier drug delivery systems","volume":"23","author":"Pan","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2026.115925_bb0270","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2007.02.010","article-title":"Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes","volume":"119","author":"Wang","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115925_bb0275","first-page":"455","article-title":"Effect of Kupffer cells depletion on ABC phenomenon induced by Kupffer cells-targeted liposomes, Asian","volume":"14","author":"Lai","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115925_bb0280","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ejpb.2012.04.023","article-title":"A frustrating problem: accelerated blood clearance of PEGylated solid lipid nanoparticles following subcutaneous injection in rats","volume":"81","author":"Zhao","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2026.115925_bb0285","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jconrel.2016.05.010","article-title":"Exploring the relationship between anti-PEG IgM behaviors and PEGylated nanoparticles and its significance for accelerated blood clearance","volume":"234","author":"Shiraishi","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115925_bb0290","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00418-022-02086-0","article-title":"A higher dose of PEGylated gold nanoparticles reduces the accelerated blood clearance phenomenon effect and induces spleen B lymphocytes in albino mice","volume":"157","author":"Abu-Dief","year":"2022","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.addr.2026.115925_bb0295","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2026.115925_bb0300","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1021\/acsnano.9b07218","article-title":"Premature drug release from polyethylene glycol (PEG)-coated liposomal doxorubicin via formation of the membrane attack complex","volume":"14","author":"Chen","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115925_bb0305","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jconrel.2021.11.042","article-title":"Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement","volume":"341","author":"Estap\u00e9 Senti","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115925_bb0310","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jconrel.2007.11.009","article-title":"The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats","volume":"126","author":"Ishida","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115925_bb0315","doi-asserted-by":"crossref","first-page":"28649","DOI":"10.1021\/acsnano.4c05087","article-title":"Nanoparticle-binding immunoglobulins predict variable complement responses in healthy and diseased cohorts","volume":"18","author":"Li","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115925_bb0320","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.879988","article-title":"PEG: will it come Back to you? Polyethelyne glycol immunogenicity, COVID vaccines, and the case for new PEG derivatives and alternatives","volume":"10","author":"Kong","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.addr.2026.115925_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102163","article-title":"Anti-PEG antibodies: current situation and countermeasures","volume":"55","author":"Fu","year":"2024","journal-title":"Nano Today"},{"key":"10.1016\/j.addr.2026.115925_bb0330","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jconrel.2019.07.005","article-title":"Liposome-induced hypersensitivity reactions: risk reduction by design of safe infusion protocols in pigs","volume":"309","author":"Fulop","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115925_bb0335","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3390\/pharmaceutics17081074","article-title":"Anti-PEG antibodies and their biological impact on PEGylated drugs: challenges and strategies for optimization","volume":"17","author":"Fu","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115925_bb0340","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaci.2015.10.034","article-title":"Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer","volume":"137","author":"Ganson","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.addr.2026.115925_bb0345","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1016\/j.vaccine.2023.05.029","article-title":"Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination","volume":"41","author":"Zhou","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2026.115925_bb0350","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/s41563-025-02383-8","article-title":"Designing around immune memory to counter PEG immunogenicity","volume":"24","author":"Chaudhary","year":"2025","journal-title":"Nat. Mater."},{"key":"10.1016\/j.addr.2026.115925_bb0355","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26873","article-title":"Outcome of pediatric patients with acute lymphoblastic leukemia\/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: a report from the children\u2019s oncology group","volume":"65","author":"Rau","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.addr.2026.115925_bb0360","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.addr.2026.115925_bb0365","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/apm.13294","article-title":"SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID-19 vaccination","volume":"131","author":"Castruita","year":"2023","journal-title":"APMIS"},{"key":"10.1016\/j.addr.2026.115925_bb0370","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.3390\/biomedicines10071538","article-title":"Vaccine mRNA can be detected in blood at 15 days post-vaccination","volume":"10","author":"Fertig","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.addr.2026.115925_bb0375","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1021\/bc200551b","article-title":"Role of the methoxy group in immune responses to mPEG-protein conjugates","volume":"23","author":"Sherman","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2026.115925_bb0380","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1248\/bpb.b12-00276","article-title":"Intravenous Administration of Polyethylene Glycol-Coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response","volume":"35","author":"Shimizu","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.addr.2026.115925_bb0385","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1021\/acs.molpharmaceut.9b00770","article-title":"Accelerated blood clearance of Nanoemulsions modified with PEG-cholesterol and PEG-phospholipid derivatives in rats: the effect of PEG-lipid linkages and PEG molecular weights","volume":"17","author":"Liu","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115925_bb0390","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41563-024-02116-3","article-title":"High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics","volume":"24","author":"Xiao","year":"2025","journal-title":"Nat. Mater."},{"key":"10.1016\/j.addr.2026.115925_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119792","article-title":"PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: faster PEG shedding attenuates anti-PEG IgM production","volume":"588","author":"Suzuki","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115925_bb0400","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2025.01.071","article-title":"Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines","volume":"380","author":"Zhang","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115925_bb0405","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jconrel.2017.01.040","article-title":"Ganglioside inserted into PEGylated liposome attenuates anti-PEG immunity","volume":"250","author":"Mima","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115925_bb0410","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/s41551-024-01256-w","article-title":"Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d","volume":"8","author":"Chaudhary","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.addr.2026.115925_bb0415","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/jps.23823","article-title":"Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery","volume":"103","author":"Abu Lila","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115925_bb0420","doi-asserted-by":"crossref","DOI":"10.1002\/marc.202500428","article-title":"Polyglycerol-based lipids: a next-generation alternative to PEG in lipid nanoparticles for advanced drug delivery systems","author":"Ensminger","year":"2025","journal-title":"Macromol. Rapid Commun."},{"key":"10.1016\/j.addr.2026.115925_bb0425","first-page":"19890","article-title":"Mitigating the effects of persistent Antipolymer immune reactions in nanomedicine: evaluating materials-based approaches using molecular imaging","volume":"18","author":"Humphries","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115925_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2025.114392","article-title":"Overcoming the PEG dilemma with poly(2-ethyl-2-oxazoline) lipids in lipid nanoparticle formulations","volume":"241","author":"Moreadith","year":"2025","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.addr.2026.115925_bb0435","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202304033","article-title":"Substituting poly(ethylene glycol) lipids with poly(2-ethyl-2-oxazoline) lipids improves lipid nanoparticle repeat dosing","volume":"13","author":"Sanchez","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.addr.2026.115925_bb0440","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jconrel.2023.07.031","article-title":"Poly(vinyl pyrrolidone) derivatives as PEG alternatives for stealth, non-toxic and less immunogenic siRNA-containing lipoplex delivery","volume":"361","author":"Berger","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115925_bb0445","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1021\/acs.biomac.8b01020","article-title":"Impact of polymer bioconjugation on protein stability and activity investigated with discrete conjugates: alternatives to PEGylation","volume":"19","author":"Morgenstern","year":"2018","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2026.115925_bb0450","doi-asserted-by":"crossref","first-page":"9264","DOI":"10.1039\/D5SC00772K","article-title":"PVAylation: precision end-functionalized poly(vinyl alcohol) for site-selective bioconjugation","volume":"16","author":"Soutar","year":"2025","journal-title":"Chem. Sci."},{"key":"10.1016\/j.addr.2026.115925_bb0455","first-page":"86","article-title":"Engineering LNPs with polysarcosine lipids for mRNA delivery","volume":"37","author":"Kang","year":"2024","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.addr.2026.115925_bb0460","doi-asserted-by":"crossref","first-page":"10634","DOI":"10.1021\/acsanm.0c01834","article-title":"Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery","volume":"3","author":"Nogueira","year":"2020","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.addr.2026.115925_bb0465","doi-asserted-by":"crossref","first-page":"32567","DOI":"10.1021\/jacs.4c11347","article-title":"Zwitterionic polymer-functionalized lipid nanoparticles for the nebulized delivery of mRNA","volume":"146","author":"Jiang","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2026.115925_bb0470","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41563-025-02240-8","article-title":"Poly(carboxybetaine) lipids enhance mRNA therapeutics efficacy and reduce their immunogenicity","volume":"24","author":"Luozhong","year":"2025","journal-title":"Nat. Mater."},{"key":"10.1016\/j.addr.2026.115925_bb0475","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijpharm.2013.07.059","article-title":"Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration","volume":"456","author":"Abu Lila","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115925_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121676","article-title":"Polyglycerol and poly(ethylene glycol) exhibit different effects on pharmacokinetics and antibody generation when grafted to nanoparticle surfaces","volume":"287","author":"Shin","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2026.115925_bb0485","doi-asserted-by":"crossref","first-page":"10980","DOI":"10.1073\/pnas.1106634108","article-title":"Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform","volume":"108","author":"Hu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2026.115925_bb0490","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.actbio.2021.03.044","article-title":"Unraveling the role of intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines","volume":"126","author":"Islam","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2026.115925_bb0495","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.chembiol.2019.02.001","article-title":"Anti-PEG antibodies inhibit the anticoagulant activity of PEGylated aptamers","volume":"26","author":"Moreno","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.addr.2026.115925_bb0500","doi-asserted-by":"crossref","first-page":"29021","DOI":"10.1021\/acsnano.4c09919","article-title":"Patient-specific nanoparticle targeting in human Leukemia blood","volume":"18","author":"Ju","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2026.115925_bb0505","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2019.08.017","article-title":"Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG","volume":"311-312","author":"McSweeney","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115925_bb0510","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jconrel.2020.10.011","article-title":"Pre-treatment with high molecular weight free PEG effectively suppresses anti-PEG antibody induction by PEG-liposomes in mice","volume":"329","author":"McSweeney","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115925_bb0515","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201801607","article-title":"Modulating targeting of poly(ethylene glycol) particles to tumor cells using bispecific antibodies","volume":"8","author":"Cui","year":"2019","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.addr.2026.115925_bb0520","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1021\/acscentsci.9b01299","article-title":"Understanding the uptake of nanomedicines at different stages of brain Cancer using a modular nanocarrier platform and precision bispecific antibodies","volume":"6","author":"Houston","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.addr.2026.115925_bb0525","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/adhm.201600263","article-title":"Overcoming instability of antibody-nanomaterial conjugates: next generation targeted nanomedicines using bispecific antibodies","volume":"5","author":"Howard","year":"2016","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.addr.2026.115925_bb0530","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1039\/C9BM00323A","article-title":"Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer","volume":"7","author":"Cheng","year":"2019","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.addr.2026.115925_bb0535","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12951-020-00680-9","article-title":"Humanized bispecific antibody (mPEG x HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer","volume":"18","author":"Cheng","year":"2020","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2026.115925_bb0540","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm1262","article-title":"Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia","volume":"15","author":"Moles","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2026.115925_bb0545","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15507","article-title":"Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy","volume":"8","author":"Su","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115925_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2025.102923","article-title":"Engineered protein corona by bispecific antibody endows liposome with enhanced tumor targeting ability and mitigated accelerated blood clearance effect","volume":"66","author":"Wei","year":"2026","journal-title":"Nano Today"},{"key":"10.1016\/j.addr.2026.115925_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102520","article-title":"Targeted mRNA delivery with bispecific antibodies that tether LNPs to cell surface markers","volume":"36","author":"Dietmair","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26001596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:51:48Z","timestamp":1783774308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X26001596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":111,"alternative-id":["S0169409X26001596"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2026.115925","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2026.115925","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115925"}}